Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wp-cerber domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /www/htdocs/w00e14a1/CPC-NEU2021/wp-includes/functions.php on line 6114
The great potential of the Vietnamese market - Chameleon Pharma Consulting
+49 30 648 35 164 service@chameleon-pharma.com

The great potential of the Vietnamese market

Ago, 2016

Viet­nam has a grow­ing pop­u­la­tion of approx­i­mately 90 mil­lion, which makes it the world’s thirteenth-most populous coun­try and the eighth-most populous coun­try in Asia. A mil­lion babies are born each year in Viet­nam, and the growing pop­u­la­tion demands high-grade med­ical ser­vices. The sec­tor is there­fore seen as a pre­mium invest­ment area for for­eign com­pa­nies involved in health­care.

Drug con­sump­tion per capita in Viet­nam is increas­ing as well—it is expected to dou­ble by 2015. The increase is fuelled by a richer and older soci­ety, as well as by an expan­sion of the country’s national insur­ance sys­tem: Today, 65% of Vietnamese people are cov­ered by the national sys­tem. By 2020, that num­ber will reach 90%.

One of the main rea­sons for the country’s increased drug con­sump­tion is a busy and stress­ful lifestyle. Peo­ple in Viet­nam exer­cise less and use more take-away food deliv­er­ies. Con­se­quently, about 22% of the pop­u­la­tion is affected by gas­troin­testi­nal (GI) prob­lems. Alco­holism is another seri­ous cause of gas­troin­testi­nal prob­lems in the country; according to the Vietnam Beverage Association, about 5% of Vietnamese cit­i­zens are alco­holics.

Viet­nam’s phar­ma­ceu­ti­cal mar­ket has tremen­dous growth poten­tial. Still, most of the drugs used in the coun­try are imported. According to the General Statistics Office, Viet­nam spent US $1.25 billion on phar­ma­ceu­ti­cal imports in 2013, up 7.1% from the previous year.

Those mar­ket indices have attracted some pio­neer­ing drug­-mak­ers. For exam­ple, Sanofi plans to invest US $75 million in a new plant in Viet­nam, which will begin operations by 2015. Some other for­eign drug­-mak­ers are part­ner­ing with their Viet­namese counterparts for man­u­fac­tur­ing and dis­tri­b­u­tion. Glax­oS­mithK­line has maintained a deal with Savipharm, a lead­ing Viet­namese phar­ma­ceu­ti­cal com­pany, since 2010. STADA has taken another approach, hav­ing bought almost half of Viet­namese drug-maker Pymepharco.

Foreign investors have traditionally paid less attention to the Viet­namese healthcare industry in com­par­i­son to many other fields like finance, real estate or tourism. Today, the sit­u­a­tion is chang­ing. Many international phar­ma­ceu­ti­cal play­ers have real­ized the great poten­tial of the Viet­namese mar­ket lies in its low cost of labour and man­u­fac­tur­ing.

CPC Press Releases on Vietnam:

Vietnam: An Overview